Management of Joint Pain Associated With Osteoarthritis of the Knee With Association of Plant Extracts.

Launched by PILEJE · Nov 25, 2016

Keywords

ClinConnect Summary

For this study, 126 patients are going to be included. They will have a supplementation of Cartimotil Fort®, from 1 to 4 capsules per day during 90 days.

on the one hand, during the two visits (inclusion and follow-up), the investigator completes the questionnaire about neuropathic pain (DN4).

on the other hand, patients complete the Osteoarthritis Symptom Inventory Scale (OASIS) 4 times : just after the inclusion visit, at day 30, at day 60 and just before the follow-up visit (day 90). He completes the Patient Global Impression of Improvement (PGII), the Minimal Clinically Important Impr...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • VAS of pain : minimum 5/10 on walking or 4/10 at rest
• • Patients with a negative PASS (patient considering that the symptomatic state is not acceptable)
• • Suffering from mono or bilateral femoro-tibial knee osteoarthrosis with painful seizures (confirmed by a radio of less than two years: stage 2 or 3 on the Kellgreen scale - clinical examination)
• • Having agreed to participate in the investigation after receiving information from the investigator
• Exclusion Criteria:
• • Patients with rheumatological disorders other than osteoarthritis
• • Patients for whom knee surgery is planned within 3 months
• • Patients who started treatment with chondroitin sulphate (or all treatments of osteoarthritis other than anti-inflammatories and analgesics) for less than one month
• • Patients with a BMI greater than 35
• • Patients with chronic pain that can interfere with knee osteoarthritis pain
• • Patients with reduced mobility or bedridden
• • Patients with cognitive impairments not able to participate in the study
• • Patients with known allergies to any of the ingredients of Cartimotil Fort®
• • Pregnant or breastfeeding patients
• • Patients who do not wish to participate in the study.